Comprehensive analysis of the amino acid metabolism-related gene signature for prognosis, tumor immune microenvironment, and candidate drugs in hepatocellular carcinoma

Yue Li, Huanye Mo, Siying Jia, Jun Wang, Ying Ma, Xin Liu, Kangsheng TuFrontiers in Immunology 2022 · DOI

TL;DR

This study identifies a novel gene signature (AAMRGS) based on amino acid metabolism that can predict prognosis, characterize the tumor immune microenvironment, and suggest potential drug sensitivities in hepatocellular carcinoma (HCC). This signature offers a new tool for personalized treatment strategies in HCC.

What Problem Does This Paper Address?

Hepatocellular carcinoma (HCC) remains a significant global health challenge, characterized by high mortality rates often due to late diagnosis and limited treatment options. While advancements in targeted therapies and immunotherapy have improved outcomes, survival benefits are often modest. Understanding the complex biological underpinnings of HCC, particularly its metabolic rewiring, is crucial for developing more effective treatments. Amino acid metabolism, a fundamental process supporting tumor growth and influencing the immune microenvironment, has been implicated in various cancers, but its specific role and potential as a predictive marker in HCC are not fully elucidated. This paper aims to address this gap by comprehensively analyzing amino acid metabolism-related genes (AAMRGs) to identify a signature that can predict HCC patient outcomes, characterize the tumor's immune landscape, and guide therapeutic decisions.

Methods

The researchers employed a multi-faceted approach, starting with data from the TCGA and ICGC databases. They utilized Non-negative Matrix Factorization (NMF), a clustering algorithm, to identify distinct molecular subtypes of HCC based on AAMRG expression. To construct a prognostic gene signature, they combined univariate Cox regression and LASSO regression to select key genes and build the Amino Acid Metabolism-Related Gene Signature (AAMRGS). The clinical significance of this AAMRGS was then evaluated using Kaplan-Meier (KM) survival analysis and time-dependent ROC curve analysis. Beyond prognosis, the study delved into the tumor's characteristics by analyzing somatic mutation data (calculating Tumor Mutational Burden - TMB), immune cell infiltration using the CIBERSORT algorithm, and immune function via single sample gene set enrichment analysis (ssGSEA). Finally, they explored drug sensitivity using the Cancer Genome Project (CGP) database and validated key gene expressions and drug effects in vitro using quantitative real-time PCR and CCK8 assays.

Datasets

  • TCGA (The Cancer Genome Atlas): Used as the primary training cohort for developing the AAMRGS and analyzing its prognostic value.
  • ICGC (International Cancer Genome Consortium): Used as an independent validation cohort to confirm the findings from the TCGA dataset.
  • Cancer Genome Project (CGP) database: Utilized to predict drug sensitivity in different AAMRGS subgroups.

No new benchmarks were introduced; the study leverages existing public datasets.

Key Insights and Ideas

  • Metabolic Heterogeneity in HCC: The study reveals that HCC tumors exhibit distinct molecular subtypes driven by amino acid metabolism, suggesting that metabolic reprogramming is not uniform across all HCC cases.
  • AAMRGS as a Prognostic Indicator: The identified AAMRGS (composed of GLS, IYD, and NQO1) demonstrates significant power in predicting patient survival, outperforming other clinical factors. This highlights the critical role of amino acid metabolism in HCC progression.
  • Linking Metabolism to the Immune Microenvironment: The AAMRGS score is strongly associated with the composition and function of the tumor immune microenvironment. High AAMRGS scores correlate with increased immunosuppressive cells and immune checkpoint expression, suggesting a more "cold" or less immunogenic tumor.
  • Metabolism Influences Drug Response: The AAMRGS effectively stratifies patients based on their sensitivity to various chemotherapeutic and targeted drugs, indicating that metabolic profiles can predict treatment efficacy.
  • TP53 Mutation and Prognosis: The study points to a higher mutation rate in TP53 in the high-risk AAMRGS group, linking this critical tumor suppressor gene's dysfunction to poorer outcomes, potentially through its role in metabolic regulation.

Key Results

  • Two distinct molecular subtypes of HCC were identified based on AAMRG expression, with one subtype showing significantly poorer prognosis.
  • The developed AAMRGS, comprising GLS, IYD, and NQO1, was validated as an independent prognostic factor in both TCGA and ICGC cohorts.
  • The AAMRGS score showed significant correlations with clinicopathological features such as pathological grade, T staging, clinical stage, vascular invasion, and virus infection.
  • Patients with high AAMRGS scores exhibited higher infiltration of immunosuppressive cells (Tregs, M2 macrophages) and increased expression of immune checkpoints (TIM3, CD96, CTLA4, TIGIT, PD-L1, PD-1, PD-L2).
  • The AAMRGS-high group showed higher sensitivity to drugs like bleomycin, gemcitabine, and paclitaxel, while the AAMRGS-low group was more sensitive to drugs like axitinib, gefitinib, and rapamycin.
  • In vitro experiments confirmed that gemcitabine significantly reduced SNU449 cell proliferation, and rapamycin inhibited Huh7 cell proliferation.

Limitations and Future Work

The authors acknowledge that their study is based on publicly available datasets. While they validated the differential mRNA expression of the signature genes in normal liver cells and HCC cell lines, and performed in vitro drug sensitivity assays, they emphasize the need for large-scale, multicenter, prospective studies to validate their findings clinically. The high heterogeneity of HCC also means that intra-tumor and surrounding microenvironment variations could influence the signature's applicability. Future work could focus on further elucidating the precise mechanisms by which amino acid metabolism influences immune cell function and drug resistance, and exploring combination therapies that target both metabolic pathways and the immune system.

Summary updated

Abstract

Our study explored the features of amino acid metabolism in HCC and identified the novel AAMRGS to predict the prognosis, immune microenvironment, and drug sensitivity of HCC patients. These findings might help to guide personalized treatment and improve the clinical outcomes of HCC.
BibTeX
@inproceedings{li2022comprehensive,
  author = {Yue Li and Huanye Mo and Siying Jia and Jun Wang and Ying Ma and Xin Liu and Kangsheng Tu},
  title = {{Comprehensive analysis of the amino acid metabolism-related gene signature for prognosis, tumor immune microenvironment, and candidate drugs in hepatocellular carcinoma}},
  booktitle = {Frontiers in Immunology},
  year = {2022},
  doi = {10.3389/fimmu.2022.1066773},
}
Figure